Xenon Pharmaceuticals Inc (XENE) exceeds patient enrollment goals in its Phase 3 XTOL2 study and maintains a robust cash runway into 2027, despite facing market competition and upcoming expenses.
Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback